Head-to-head · free

NKE vs The Precision Peptide Company

NKE vs PNGAF — return on capital, cash generation, margins and balance sheet side by side.

NKE

0 / 0

measures where NKE leads

PNGAF

0 / 0

measures where PNGAF leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNKE · FY2026PNGAF
Revenue$46.4B—
Net income$3.1B—
Revenue growth (yearly, multi-year)-0.2%—
Free cash flow$2.2B—
Free cash flow margin4.7%—
Net cash / (debt)(3.5B)—
ROIC11.8%—
Return on equity22.1%—
Gross margin42.9%—
Operating margin8.2%—
Net debt / EBITDA0.08x—

Figures are as reported by each company; latest fiscal year shown.

Where NKE's cash went (FY2026)

Capital spending
$684.0M
Buybacks
$146.0M
Dividends
$2.4B
Acquisitions
$0
Net debt issued / (repaid)
$0
Full NKE profile →

Where The Precision Peptide Company's cash went

Not reported yet.

Full PNGAF profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons